Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 968897

A rapid HLA-D matching method using PHA blasts as responding cells (preliminary data on PHA blasts HLA-D typing).

C Mawas·D Charmot·A Comoy·M Sasportes
View original source ↗Export metadata ↓

Abstract

Day 3-4 PHA stimulated lymphocytes were found to respond against HLA-D without any period of latency, thus allowing a discriminative MLR reading as early as 24-48 h. The test is therefore characterized by the minute number of responding cells necessary (5 X 10(3)), a one-way reaction without additional treatment of the stimualtion normal lymphocytes (5 x 10(4)), and the rapid obtaining of data. We found the preliminary data testing its concordance with classical HLA-D typing encouraging and worthy of being tested on a larger scale. Using mitogen stimulated recipient cells stored frozen, HLA-D matching with potential donors was found to be feasible within 24-48 h. The mechanism of such a prompt response by mitogen stimulated lymphocytes is unknown but appears to be independent of the nature and dose of a given mitogen.

Explore related subjects

HLA AntigensHeterozygoteHistocompatibility TestingHumansLectinsLymphocyte ActivationLymphocytesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Mawas, D Charmot, A Comoy, M Sasportes. 1976. A rapid HLA-D matching method using PHA blasts as responding cells (preliminary data on PHA blasts HLA-D typing).. https://pubmed.ncbi.nlm.nih.gov/968897/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Soluble HLA revisited.

The goal of this editorial is to revisit soluble human leukocyte antigens (sHLA) and to highlight the findings reported by Albitar et al. in this issue on the relation between sHLA levels in Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). We will review key aspects of sHLA including soluble HLA-G, which has received a lot of attention in recent publications. We will then address the role of sHLA in lymphoproliferative diseases and in solid organ tumors. Lastly, we will comment on the results of Albitar et al. and their relevance to clinical application in NHL.

HLA Antigens↗
PubMed2006

Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma.

Tumor growth and dissemination depend partly on the reactivity of natural killer (NK) cells and T cells expressing NK-associated receptors. Their effector functions are regulated by an array of activating and inhibitory cell surface receptors with MHC class I ligand specificity, such as the killer immunoglobulin-like receptors (KIRs). Given the extensive genomic diversity of KIRs and their HLA ligands, it is reasonable to speculate that HLA, KIR gene variations and specific KIR-ligand combinations will have an impact on disease susceptibility and/or progression. Here, we discuss how KIR genotypes and KIR/HLA immunogenetic profiles may be involved in tumorigenesis, especially in malignant melanoma (MM). A hypothetical model of the impact of KIR/ligand combinations on immune responses in MM is proposed.

HLA Antigens↗